Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines ...

Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) ...

Quarter Highlighted by GEO-MVA Acceleration Amid Global Mpox Emergency, Gedeptin(R) Expansion Into New Solid Tumor Programs, and Strong GEO-CM04S1 Clinical Data in Immunocompromised Patients Company ...

Colas and colleagues used Nordic registries data with family linkage to study 5,721 offspring: 1,950 in Denmark, 1,416 in Norway, and 2,355 in Sweden. Children had fathers who were exposed to ...

The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) from Outlook ...

Europe’s shift beyond animal testing depends on partnership, the EPAA’s collaborative model is emerging as the engine driving ...

Detailed price information for Fate Therapeutics (FATE-Q) from The Globe and Mail including charting and trades.

Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom's Macroglobulinemia in 2026 Following Advice and Guidance from Scienti ...

BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ ...

Strategic Implications: Analytical findings reported today underscore ABP-450’s potential to become the first full label therapeutic biosimilar to BOTOX® in the U.S., positioning AEON to address a >$3 ...

Combined transactions will strengthen balance sheet and reduce outstanding debt by more than 90% - - $6 million PIPE financing with potential for over $7 million of additional capital via ...

Our productive engagement with the European Medicines Agency (EMA) highlighted by confirmation of eligibility to submit for a conditional ...